Q3 EPS Estimate for Edwards Lifesciences Lifted by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research upped their Q3 2025 earnings estimates for Edwards Lifesciences in a research report issued on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $0.60 per share for the quarter, up from their prior forecast of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.59 EPS.

A number of other brokerages have also commented on EW. Evercore ISI lowered their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Truist Financial dropped their price target on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Piper Sandler reduced their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Finally, Oppenheimer reissued an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

NYSE EW opened at $71.56 on Monday. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock’s 50-day moving average is $67.83 and its two-hundred day moving average is $75.37. The firm has a market cap of $42.20 billion, a P/E ratio of 10.33, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp raised its stake in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares during the period. Geode Capital Management LLC lifted its holdings in Edwards Lifesciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after buying an additional 284,918 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after acquiring an additional 806,705 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,000 shares of company stock worth $2,657,000. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.